Mito-Esc Amphiphile siRNA Delivery Nanoparticles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid delivery methods face challenges such as rapid degradation in biological fluids, limited cellular uptake, and inefficient intracellular delivery due to the hydrophilic and high molecular weight nature of nucleic acids, which compromises their therapeutic efficacy.
Innovation Solution
A phosphonium amphiphile, specifically triphenylphosphonium cation (TPP+) coupled with esculetin (Mito-Esc), forms self-assembled nanoparticles to facilitate the delivery of nucleic acids like siRNA across the plasma membrane, leveraging its amphiphilic properties for enhanced cellular uptake and mitochondrial targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naked or encapsulated nucleic acids are introduced into a carrier for combination with biological fluids, then the nucleic acids can be delivered to target cells, but they rapidly degrade in biological fluids by extra- and intracellular enzymes before reaching the target cells
Solution Approach 1:
The patent employs delivery vectors as intermediary carriers that protect nucleic acids from enzymatic degradation in biological fluids. These vectors serve as a protective medium that allows nucleic acids to traverse the hostile biological environment and reach target cells intact, resolving the contradiction between stability and delivery time.
Solution Approach 2:
The patent modifies the chemical and physical parameters of nucleic acids through conjugation with delivery vectors, altering their stability, solubility, and cellular uptake properties. This parameter modification enables nucleic acids to maintain stability in biological fluids while facilitating their transport to target cells.
2Reliability
If nucleic acids are administered, then they can potentially treat diseases, but they have very limited cellular uptake because of their hydrophilic nature and high molecular weight
Solution Approach 1:
The patent uses delivery vectors as intermediary carriers that bridge the gap between hydrophilic nucleic acids and the cellular membrane. These vectors facilitate cellular uptake by providing a suitable interface that overcomes the hydrophilic barrier and enables efficient entry into target cells.
Solution Approach 2:
The patent creates composite structures by conjugating nucleic acids with delivery vectors, forming hybrid molecules that combine the therapeutic properties of nucleic acids with the cell-penetrating capabilities of the vectors. This composite approach resolves the contradiction between maintaining nucleic acid functionality and achieving cellular uptake.
3Reliability
If a small fraction of nucleic acids is taken up by cells, then some intracellular delivery occurs, but the internalized nucleic acids are trapped in endosomes that convert into lysosomes where they are digested, precluding them from reaching cytoplasmic or nuclear targets
Solution Approach 1:
The patent employs delivery vectors as intermediary agents that guide nucleic acids through the complex intracellular trafficking pathway. These vectors facilitate escape from endosomal/lysosomal compartments and guide the nucleic acids to their intended cytoplasmic or nuclear destinations, simplifying the overall delivery process.
Solution Approach 2:
The patent incorporates endosome-escaping functionalities into the delivery vectors before cellular uptake occurs. This preliminary preparation enables the vectors to proactively prevent nucleic acid degradation by escaping the endosomal pathway before lysosomal digestion can occur, thereby ensuring successful delivery to the target compartment.
4Ease of operation
If delivery vectors are incorporated into the therapeutic composition, then intracellular delivery to the target site is enabled, but the therapeutic potential of the active RNA agent is limited
Solution Approach 1:
The patent designs delivery vectors as temporary intermediaries that facilitate delivery but do not permanently associate with or inhibit the RNA agent's therapeutic function. The vectors enable intracellular delivery while being designed to release or dissociate from the RNA agent once inside the target cell, thereby preserving the full therapeutic potential of the RNA agent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Mito-Esc effectively delivers nucleic acids into target cells, demonstrating high transfection efficiency and preferential cytotoxicity in cancer cells while maintaining low toxicity in normal cells, thereby improving the therapeutic potential of nucleic acid-based treatments.
Implementation Method 1
forms self-assembled nanoparticles to facilitate the delivery of nucleic acids
Implementation Method 2
leveraging its amphiphilic properties for enhanced cellular uptake
Implementation Method 3
effectively delivers nucleic acids into target cells... across the plasma membrane
Data Source
AI summary
There is provided a complex of a 6,7-dihydroxy coumarin phosphonium amphiphile together with a negatively charged agent. The complex self-assembles into a nanoparticle or non-viral vector for facilitating delivery of the negatively charged agent. The negatively charged agent may be a therapeutic agent or a diagnostic agent. Thus, the present invention provides a method of delivery of such negatively charged agents to a target cell, and in particular facilitates delivery of a therapeutic or diagnostic agent across the plasma membrane, as well as a method of treatment or diagnosis via delivery of the therapeutic or diagnostic agent. The 6,7-dihydroxy coumarin phosphonium amphiphile can be Mito-Esc and the negatively charged agent can be a nucleic acid such as siRNA. Additionally, the 6,7-dihydroxy coumarin phosphonium amphiphile is believed to be effective in the treatment of cancer.